Reducing addiction, promoting competition FDA priorities for 2018
The Food and Drug Administration today announced four priority areas for additional policy activity in 2018: reducing addiction to opioid drugs and cigarettes; promoting innovation and competition; empowering consumers to make informed decisions; and strengthening the FDA workforce. Specific policy efforts include new steps to support and streamline development and approval of treatments that address addiction; reducing burdens for creating and approving generic drugs; and extending new hiring and pay authorities to recruit and retain FDA staff.
Related News Articles
Headline
To encourage drug companies to seek approval for over-the-counter versions of naloxone, an emergency treatment for opioid overdose, the Food and Drug…
Headline
Patients in the most rural counties had an 87 percent greater chance of receiving an opioid prescription from their primary care provider between January 2014…
Headline
Continued rising drug prices, as well as shortages for many critical medications, are disrupting patient care and forcing hospitals to delay infrastructure and…
Headline
The New Hampshire Hospital Association, along with hospitals across the state, recently filed a motion to intervene in a federal lawsuit filed against the…
Headline
U.S. overdose death rates linked to synthetic opioids increased more than 45 percent in 2017, likely driven by illicitly manufactured fentanyl, according to a…
Headline
The Health Resources and Services Administration recently launched a program to provide eligible health care clinicians with student loan repayment assistance…